Transformation of a myelodysplastic syndrome to acute myeloid leukemia and concurrent necrotizing sweet syndrome

Olga Vera-Lastra,1,2 Arturo Olvera-Acevedo1,2 Nancy Pulido-Díaz,3 Marissa de Jesús Quintal-Ramírez,4 Irvin Ordoñez-González,4 Erik Cimé-Aké,1,2 María Pilar Cruz-Domínguez,4a,2 Gabriela Medina1,2

1Internal Medicine Department, Hospital de Especialidades Centro Médico Nacional La Raza, IMSS, Mexico City; 2Universidad Nacional Autónoma de México, Mexico City; 3Dermatology Department, Hospital de Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City; 4Pathology Department, Hospital de Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City; 5Research Division, Hospital de Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City; 6Universidad Veracruzana, Veracruz; 7Translational Research Unit, Hospital de Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City; 8Research Division, Hospital de Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City; 9Universidad Veracruzana, Veracruz; 10Translational Research Unit, Hospital de Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City; 11Universidad Veracruzana, Veracruz; 12Research Division, Hospital de Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City

Abstract

The Sweet’s syndrome, is an inflammatory skin disorder characterized by extensive infiltration of neutrophils in the dermis with extension to the subcutis, known as acute febrile neutrophilic dermatosis. It may occur as a paraneoplastic syndrome. To our knowledge, there are currently few reports about transformation of a myelodysplastic syndrome to acute myeloid leukemia and concurrent necrotizing Sweet syndrome in the literature. Herein we describe an unusual case in a young patient with these characteristics that evolved to a fatal outcome.

Case Report

A 23-years-old female patient, with a history of marijuana addiction for one year, tobacco and alcohol consumption since the age of 17, three abortions before 10 weeks of gestation, previously diagnosed in May 2012, with Human Papillomavirus (HPV) infection by cervical cytology and aplastic anemia by bone marrow aspiration (BMA). She received treatment with Antithymocyte Globulin for 2 cycles (May 2012 and April 2014) and posteriorly Cyclosporin A, with subsequent liver toxicity, changing to Mycophenolate Mofetil and Danazol, with a partial response, requiring multiple hospitalizations and transfusion support, with more than 40 units of globular packages, complicating with transfusional hemosiderosis, treated with Deferasirox. In May 2015, she presented cellulitis of the right thoracic limb, with spontaneous resolution and a secondary atrophic scar. In November 2015, she began with asthenia, adynamia and fever up to 41ºC, predominantly in the evening and a nodular lesion of 3 cm diameter in the upper inner quadrant (UIQ) of the right breast, which increased in size progressively, with very painful violaceous skin lesions, evolving to confluent blisters and later ulceration with non-purulent secretion and necrosis (Figure 1A). She was treated with Dicloxacillin, Piperacillin / Tazobactam and Carbapenemic. In the absence of improvement, stage IIIIB breast cancer was suspected, so she was referred in December 2015 to a tertiary level hospital. Upon admission, it was documented the lesion in the right breast, with bleeding nipple, as well as confluent blisters and edema on the outer side of the left thigh (Figure 1B,C). The patient had a non-reactive viral
Discussion

We described a case in a young patient with aplastic anemia that evolved to myelodysplastic syndrome and further to acute myeloid leukemia with Sweet syndrome. This hematologic disorder is the most common associated malignancy, being important to carry out the differential diagnosis since breast cancer was initially suspected.1

Hematologic disorders represent more than 15-20% of MASS, being AML and MS the most common.5

Few cases coincident with MS, AML and SS have been reported in the literature as the case of a 15-year-old girl who presented these three entities with FLT3 and NPM1 type A mutations. Risk factors for MASS in AML encompass deletion of chromosome 5 or 5q, presence of FLT3 mutations, and AML with myelodysplasia-related features. Unfortunately, our patient did not have a karyotype due to a rapid adverse clinical course.7

Pourmoussa and Kwan reported another case of an extremely rapid transformation from MS with concomitant SS to AML, in an elderly patient.8 Our patient also followed that sequence with a fatal ending. Myelodysplastic Syndrome can evolve into AML, which often leads to a poor prognosis.

The outlook of SS is little known, with an incidence of 2.7 at 3 cases/100,000 in the general population.9 The diagnosis of SS associated with MS with transformation to AML has a low incidence and it is scarcely described in the literature, but of importance in the diagnostic suspicion.

In Mexico, a recent multicenter study identified that AML presents at a younger age in comparison with developed countries, with a median age of onset of 47 years, however this patient presented AML at an earlier age.10

SS related to hematological neoplasia may present prior to or concomitant to the primary diagnosis, that means a paraneoplastic event, in the patient occurred concomitantly with acute myeloid leukemia, similar to that reported by Mo et al.11

Necrotizing SS or acute necrotizing neutrophilic dermatosis is an infrequent and severe variant, distinguished by aggressive skin lesions that can easily simulate and be mistaken for necrotizing soft tissue infections such as necrotizing fasciitis or pyoderma gangrenosum. It is characterized by hyperpyrexia, neutrophilia and painful skin lesions that can be single or multiple, be vesicular, pustular, bullous or ulcerative, and mainly necrosis.12

The term Necrotizing SS proposed in 2012 and to date only 4 cases have been reported worldwide, in which patients had concealed hematological diseases and histopathological findings with necrosis of the fascia and fat, simulating necrotizing neutrophilic dermatosis.

Reference

1. Yamane A, et al. Ann Hematol. 2015;94(11):1891-9. 
2. Pourmoussa N, et al. J Eur Acad Dermatol Venereol. 2015;29(7):1274-5.
fasciitis. Previous cases were males with a median age of 57.5 years of onset, all of them with underlying hematological diseases, however the present case was in a very young woman with an aggressive clinical course.13

This entity may be confused with other pathologies, among the most common differential diagnoses that mimic SS are bacterial, mycobacterial, fungal, and parasitic infections. To avoid this, a biopsy should be considered to detect characteristic features consistent with SS.5 This disease has a low incidence and is little described in the literature. Communications of fatal outcomes of Sweet’s syndrome are uncommon, as it is depicted as an idiopathic chronic systemic inflammatory response syndrome or as in this case, related to malignancy with a fatal outcome in a young patient.1,14

Conclusions

Sweet syndrome is a rare entity that may appear as a sign of malignancy, as in the present case, in a young patient with fatal outcome. It is necessary to have a high index of suspicion to recognize it and identify the underlying disorder.

References

1. Villarreal CD, Ocampo J, Villarreal A. Sweet Syndrome: A review and update. Actas Dermosifiliogr 2016;107:369-78.
2. Zheng S, Li S, Tang S, et al. Insights into the characteristics of Sweet Syndrome in patients with and without hematologic malignancy. Front Med 2020;7:1-5.
3. Dan H, Yanmei L, Yue X, Xian J. Sweet syndrome associated with malignancies: A retrospective analysis of 25 patients from West China hospital. Dermatol Ther 2020;1:1-14.
4. Gomes D, Campos G, Macchione J, Costa G. Paraneoplastic Sweet’s syndrome. Ann Bras Dermatol 2018;93:576-8.
5. Clark AK, Sarcon AK, Fung MA, et al. Malignancy-associated Sweet syndrome: acute febrile neutrophilic dermatosis associated with recurrence of metastatic cervical cancer. Dermatol Online J 2017;23:1-5.
6. Cohen PR, Kurzrock R. Sweet’s syndrome and malignancy. Am J Med 1987;82:1220-6.
7. Chen SH, Kuo YT, Liu YL, et al. Acute myeloid leukemia presenting with Sweet syndrome: A case report and review of the literature. Pediatr Neonatol 2016;58:283-4.
8. Pourmoussa A, Kwan K. An unlikely rapid transformation of myelodysplastic syndrome to acute leukemia: A case report. Perm J 2017;21:16-91.
9. Djien V, Wallach D. Sweet’s syndrome: practical conduct. Ann Dermatol Venereol 1999;126:343-7.
10. Demichelis R, Zapata N, Leyto F, et al. Acute myeloid leukemia in Mexico: the specific challenges of a developing country. Results from a multicenter national registry. Clin Lymphoma Myeloma Leuk 2019;20:e295-w303.
11. Mo W, Wang X, Wang Y, et al. Clonal neutrophil infiltrates in concurrent Sweet’s syndrome and acute myeloid leukemia: A case report and literature review. Cancer Genet 2018;226:11-6.
12. Lipof JS, Beck LA, Reddy SC, et al. Necrotizing Sweet Syndrome of the Upper Extremity After Elective Hand Surgery. J Hand Surg Am 2018;43:e1-6.
13. Minamiyama R, Asai J, Kaneko Y, et al. Necrotizing Sweet syndrome in a patient with myelodysplastic syndrome. Clin Exp Dermatol 2017;42:436-8.
14. Rochet NM, Chavan RN, Cappel MA, et al. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol 2013;69:557-64.